Silence is the only listed RNAi player in Europe and a pioneer in this technology. Through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger RNAi in specific cell types. Our inventions are protected by a broad intellectual property estate, which is a fundamental asset. Together with our progress, the fact that the field is generally maturing means that RNAi drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients.
Full Year Results 2017Download
Half Year Results 2018367KB Download
Full Year Results 2017298KB Download
Half Year Results 2017154KB Download
Full Year Results 2016898KB Download
Half Year Results 2016614KB Download
Annual Report 20172MB Download
Annual Report 20161MB Download
Annual Report 2015978KB Download
Annual Report 20149MB Download
Annual Report 2013928KB Download
OTS Seattle 2018 - Pipeline and platform progress for hepatocyte-targeted siRNAs (presentation)1MB Download
OTS Seattle 2018 - Improved in vivo potency for divalent GalNAc-siRNA conjugates (poster)743KB Download
Half Year Results 2018 Presentation586KB Download
European Hematology Association 2018 - SLN124976KB Download
BIO partnering - June 20181MB Download
Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.
We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.